Señales en vivo de LUCD | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 16:00):

Stats
Volumen de hoy	275 028
Volumen promedio	174 998
Capitalización de mercado	36.22M
EPS	$-0.250 ( 2024-03-26 )
Próxima fecha de ganancias	( $-0.270 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00500 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sparks Ronald M	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Lapidus Stanley	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Cox James L	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sokolov Jacque J	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
33.30
Last 57 transactions
Buy: 13 183 319 \| Sell: 4 158 892

Volumen Correlación

Largo: 0.04 (neutral)

Corto: -0.53 (weak negative)

Signal:(59.269) Neutral

Lucid Diagnostics Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lucid Diagnostics Inc. Correlación - Moneda/Commodity

0.33
( neutral )

-0.58
( weak negative )

0.00
( neutral )

0.86
( strong )

0.47
( neutral )

Lucid Diagnostics Inc. Finanzas

Annual	2023
Ingresos:	$2.43M
Beneficio Bruto:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
Ingresos:	$2.43M
Beneficio Bruto:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
Ingresos:	$377 000
Beneficio Bruto:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
Ingresos:	$500 000
Beneficio Bruto:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.